keyboard_arrow_up

Cognitive Impairment Associated With Schizophrenia (CIAS) - Therapeutics Assessment Pipeline Review, H1 2014

RnRMarketResearch.com adds “Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline Review, H1 2014” to its store. The report provides an overview of the Cognitive Impairment Associated With Schizophrenia (CIAS)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report available @ http://www.rnrmarketresearch.com/cognitive-impairment-associated-with-schizophrenia-cias-pipeline-review-h1-2014-market-report.html .

Scope

  • The report provides a snapshot of the global therapeutic landscape of Cognitive Impairment Associated With Schizophrenia (CIAS)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Cognitive Impairment Associated With Schizophrenia (CIAS) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Cognitive Impairment Associated With Schizophrenia (CIAS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

List of Tables

Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS), H1 2014 10
Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS) - Comparative Analysis, H1 2014 11
Number of Products under Development by Companies, H1 2014 13
Number of Products under Development by Companies, H1 2014 (Contd..1) 14
Comparative Analysis by Late Stage Development, H1 2014 15
Comparative Analysis by Clinical Stage Development, H1 2014 16
Comparative Analysis by Early Stage Development, H1 2014 17
Products under Development by Companies, H1 2014 18
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Eli Lilly and Company, H1 2014 19
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Merck & Co., Inc., H1 2014 20
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Takeda Pharmaceutical Company Limited, H1 2014 21
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Avineuro Pharmaceuticals, Inc., H1 2014 22
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Novartis AG, H1 2014 23
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by FORUM Pharmaceuticals Inc., H1 2014 24
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by H. Lundbeck A/S, H1 2014 25
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Pfizer Inc., H1 2014 26
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Suven Life Sciences Ltd., H1 2014 27
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Mithridion, Inc., H1 2014 28
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by CoMentis, Inc., H1 2014 29
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Upsher-Smith Laboratories, Inc., H1 2014 30
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Siena Biotech S.p.A., H1 2014 31
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Dart NeuroScience LLC, H1 2014 32
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Intra-Cellular Therapies, Inc., H1 2014 33
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Amarantus Bioscience Holdings, Inc., H1 2014 34
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Mnemosyne Pharmaceuticals, Inc., H1 2014 35
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2014 36
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by AbbVie Inc., H1 2014 37
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Saniona AB, H1 2014 38
Assessment by Monotherapy Products, H1 2014 39
Number of Products by Stage and Target, H1 2014 42
Number of Products by Stage and Mechanism of Action, H1 2014 45
Number of Products by Stage and Route of Administration, H1 2014 46
Number of Products by Stage and Molecule Type, H1 2014 47
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics - Recent Pipeline Updates, H1 2014 78
Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects, H1 2014 87
Cognitive Impairment Associated With Schizophrenia (CIAS) - Discontinued Products, H1 2014 88

Browse more reports on Mental Illness Drugs Market @ http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/mental-illness-drugs .

About Us:

RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.